Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin
Hepatology,  Clinical Article

Jacobson IM et al. – Although a stopping rule of detectable HCV–RNA at Week 12 would forfeit some SVR cases, Week–12 HCV–RNA levels ≥100 IU/mL almost universally predicted failure to achieve SVR in both treatment–naïve and treatment–experienced patients. In boceprevir recipients, the combination of stopping rules of HCV–RNA ≥100 IU/mL at Week 12 and detectable at Week 24 maximized early discontinuation of futile therapy while minimizing premature treatment discontinuation.

Methods
  • Exploratory post–hoc analyses using SPRINT–2 (treatment–naïve) and RESPOND–2 (prior treatment–experienced) were undertaken to determine if protocol–specified stopping rules (detectable HCV–RNA at Week 24 for SPRINT–2 and at Week 12 for RESPOND–2) could be refined and harmonized.

Results
  • In SPRINT–2, a Week–12 rule with a HCV RNA cut–off of ≥100 IU/mL would have discontinued therapy in 65 of 195 failures (sensitivity 33%) without sacrificing a single SVR out of 475 successes (specificity 100%).
  • Viral variants emerged after Week 12 in 36 (73%) of 49 evaluable patients who would have discontinued at Week 12 using a ≥100 IU/mL rule.
  • In RESPOND–2, 5 of 6 patients with Week–12 HCV–RNA levels between LLD (9.3 IU/mL) and LLQ (25 IU/mL) who continued therapy despite the protocol–stipulated futility rule achieved SVR; one additional patient with a Week–12 HCV–RNA level of 148 IU/mL also continued therapy, had undetectable HCV–RNA at Week 16, and attained SVR.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

1 Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study Digestive and Liver Diseases, August 4, 2014    Clinical Article

2 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , June 25, 2014    Evidence Based Medicine    Clinical Article

3 Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years Journal of Crohn's and Colitis, September 8, 2014    Clinical Article

4 Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients Clinical Gastroenterology and Hepatology , September 19, 2014    Clinical Article

5 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , September 25, 2014    Clinical Article

6 Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study Gut, October 21, 2014    Clinical Article

7 Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study Journal of Crohn's and Colitis, August 27, 2014    Clinical Article

8 Long intestinal tube splinting really prevent recurrence of postoperative adhesive small bowel obstruction? A study of 1071 cases The American Journal of Surgery, July 23, 2014    Clinical Article

9 Sleep duration affects risk for ulcerative colitis: a prospective cohort study Clinical Gastroenterology and Hepatology , October 1, 2014    Clinical Article

10 Diet and inflammatory bowel disease: review of patient-targeted recommendations Clinical Gastroenterology and Hepatology , October 10, 2014    Review Article

11 Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology, August 22, 2014    Clinical Article

12 The risk of colorectal cancer in patients with ulcerative colitis Digestive Diseases and Sciences, October 16, 2014    Clinical Article

13 Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment Alimentary Pharmacology and Therapeutics, October 9, 2014    Clinical Article

14 Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis Gastroenterology, October 7, 2014    Evidence Based Medicine

15 Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: A meta-analysis Clinical Gastroenterology and Hepatology , September 26, 2014    Evidence Based Medicine

16 Salt tea consumption and esophageal cancer, a possible role of alkaline beverages in esophageal carcinogenesis International Journal of Cancer, September 12, 2014    Clinical Article

17 Comparative effectiveness of immunosuppressant and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis Gastroenterology, October 29, 2014    Evidence Based Medicine

18 Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: A diagnostic meta-analysis Full Text BMC Gastroenterology, July 14, 2014    Free full text    Evidence Based Medicine

19 Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis Clinical Gastroenterology and Hepatology , October 2, 2014    Clinical Article

20 Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ultra 1, 2, and 3 The American Journal of Gastroenterology, September 10, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore